idc btig estim compani document
million except per share amount
deliv good manag remain bullish
valuat seem reflect maintain neutral
overal take-away busi model
larg intact compani abil consist deliv high-single-digit
organ sale growth slightli better model owe
establish pharma nutrit upsid devic result revenu in-
line grow importantli high-growth franchis within devic libr
mitraclip show littl sign slow improv year
respect surpris accompani initi guidanc
top-lin outlook alreadi telegraph fall
ebit margin pressur invest increas manufactur
capac alin libr mitraclip clip improv
oper leverag seen last two year
continu see littl risk execut howev much good news appear
bake stock premium valuat neutral stanc
stretch limit financi forecast concern around
fundament though still room run growth franchis think
well contempl number sens fewer opportun drive meaning
upsid
wait game icgm bullish around overal libr franchis
unchang diabet franchis grew robust rate come fairli
close street expect libr instal base continu expand reach
user date much-await icgm offer manag fairli
non-committ timelin instead growth remain predic
distribut payor coverag manufactur capac focu
mitraclip larg under-penetrated room estim
mitraclip grew quarter drive full-year sale
growth continu support improv penetr exist
account clinical/field sale expans europ seem whatev
neg impact conflict studi mitra fr less favor result
coapt larg manag approv function mr
coverag continu expect though manag still envis
tone around potenti still lukewarm compani continu activ
de-lev end year debt/ebitda benefit merger-
synergi dissip recent growth driver point matur
investor hope increas appetit manag tone
rather dismiss potenti sidetrack bull case sustain
revenu growth out-year
valuat share trade ep estim mid-teen premium
large-cap peer group share may advanc strong market
execut risk modest peak histor multipl provid littl room
error maintain neutral rate risk page
abbott rate neutral recent year abbott share outperform peer overal market
benefit solid pipelin launch high-growth area diabet structur heart diagnost
remain posit base busi see pathway toward drive high-singl digit revenu growth although
mitraclip still modest portion busi still earli stage penetr suggest signific
runway ahead said share trade mid-teen premium comp group feel share
reimburs approv coverag decis
stabl procedur growth price
expans current tam
cut reimburs
abbott one largest
nutrit diagnost
report revenu slightli street estim constant currenc growth benefit
easier y/i comparison come better forecast better establish pharma nutrit result
devic result devic segment revenu consolid sale in-lin street estim better hf
neuromod result offset weaker ep result vascular diabet result fairli consist street model
manag comment improv traction cardiomem less-discuss offer within heart failur
portfolio cardiomem sale near enrol continu compani guide-hf trial
use appeal ncd reconsider
segment turn diagnost organ sale growth led solid growth core lab alin
growth continu above-market europ meanwhil establish pharma perform better
forecast sale key emerg market includ india brazil russia china grew organ basi
lastli organ nutrit sale growth better model perform broad-bas strong growth
seen southeast asia latin america
profit metric gross margin forecast sg spend wors
model partial offset came better estim overal ebit margin
miss model line lower interest expens help penni favor tax
rate boost ep aggreg adjust ep came penni forecast
actualsbtig estimate variancetot ebita ebitda incom net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
make chang revenu ep estim kept organ sale growth forecast
today currenc estim less fx headwind previous forecast help
report sale estim maintain adj ep estim
abbott rate neutral recent year abbott share outperform peer overal market benefit
solid pipelin launch high-growth area diabet structur heart diagnost remain
posit base busi see pathway toward drive high-singl digit revenu growth although mitraclip
still modest portion busi still earli stage penetr suggest signific runway ahead
said share trade mid-teen premium comp group feel share rel valuat
exhibit comp tabl large-cap peer
 net ep gross bpsadj ebit bp btig estim compani filingsnewold changecagrntm johnsonjnjnot pt fishertmobuy dickinson bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/sal
abbott incom statement sale ex oper interest incom incom tax expens net ep methodology/abt share net incom ep incl disc marginsgross expensescog oper expens ep btig estim compani report
abbott segment y/i y/i y/i y/i y/i medic devic report pre-acqestablish pharmaceuticalkey emerg market y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth btig estim compani report
abbott segment laboratori y/i laboratori y/i growth laboratori y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth diagnost y/i diagnost y/i growth diagnost y/i growth oper adj y/i y/i growth y/i growth oper adj btig estim compani report
abbott segment devic ep restat onwardsrhythm manag us restat onward move icm y/i manag restat onward move icm y/i growth manag y/i growth ep restat onwardselectrophysiolog us restat onward move icm y/i restat onward move icm y/i growth y/i growth failur y/i failur y/i growth failur y/i growth y/i y/i growth y/i growth heart y/i heart y/i growth heart y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth devic y/i devic y/i growth devic y/i growth totaltot report segment us y/i report segment y/i report segment ww y/i btig estim compani adjust stj acquisit optic divestitur
btig cover compani mention report
appendix analyst certif import disclosur
